Entera Bio is a pharmaceutical company developing large molecule drugs for unmet medical needs. EB612 and EB613 are its product candidates; EB612 is being tested for hypoparathyroidism, while EB613 has completed Phase II trials for osteoporosis and is also in Phase I trials for non-union fractures. Entera Bio has a research agreement with Amgen to develop treatments for inflammatory diseases and other serious illnesses.